SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-039408
Filing Date
2023-08-08
Accepted
2023-08-08 09:03:02
Documents
61
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q inzy-20230630.htm   iXBRL 10-Q 2141240
2 EX-31.1 inzy-ex31_1.htm EX-31.1 20682
3 EX-31.2 inzy-ex31_2.htm EX-31.2 21556
4 EX-32.1 inzy-ex32_1.htm EX-32.1 12031
5 EX-32.2 inzy-ex32_2.htm EX-32.2 12246
  Complete submission text file 0000950170-23-039408.txt   7355845

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT inzy-20230630_pre.xml EX-101.PRE 293248
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT inzy-20230630.xsd EX-101.SCH 40807
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT inzy-20230630_def.xml EX-101.DEF 150812
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT inzy-20230630_cal.xml EX-101.CAL 38768
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT inzy-20230630_lab.xml EX-101.LAB 409274
55 EXTRACTED XBRL INSTANCE DOCUMENT inzy-20230630_htm.xml XML 1284143
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39397 | Film No.: 231149548
SIC: 2834 Pharmaceutical Preparations